Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Shuttle Pharmaceuticals is a clinical-stage oncology company developing radiation sensitizers to enhance the effectiveness of radiotherapy in cancer treatment. The company's lead candidate, Ropidoxuridine, is in Phase 2 trials for glioblastoma and other solid tumors. With no revenue, negative operating cash flow of approximately $6M annually, and a 93.6% one-year stock decline, SHPH represents a high-risk, binary-outcome biotech investment dependent entirely on clinical trial success and capital raising ability.
SHPH operates a classic clinical-stage biotech model: raise capital through equity offerings and grants, invest in clinical trials to prove drug efficacy and safety, then either partner with larger pharma companies for commercialization (receiving upfront payments, milestones, and royalties) or pursue independent commercialization post-FDA approval. The company's radiation sensitizer approach targets a niche within oncology where standard radiotherapy could be enhanced, potentially commanding premium pricing if differentiation is proven. Current burn rate estimated at $1.5-2M per quarter based on operating cash flow metrics. No pricing power until clinical validation achieved.
Phase 2 clinical trial data readouts for Ropidoxuridine in glioblastoma - interim analysis results or final efficacy/safety data
FDA regulatory milestones - IND approvals for new indications, Fast Track or Orphan Drug designations
Capital raising announcements - equity offerings, warrant exercises, or dilutive financings that impact share count
Partnership or licensing deals with larger pharmaceutical companies for development/commercialization rights
Patent grants or intellectual property developments protecting radiation sensitizer technology platform
Clinical trial failure risk - Phase 2 trials have approximately 30% historical success rate in oncology; negative efficacy data would likely render equity value near-zero
Regulatory pathway uncertainty - FDA approval requirements for radiation sensitizers may require larger, longer trials than currently planned, exhausting capital before commercialization
Reimbursement uncertainty - even with FDA approval, payer coverage for adjunctive radiation therapies is unpredictable, affecting commercial viability
Larger oncology players (Roche, Merck, Bristol Myers) developing competing radiation enhancement approaches with vastly superior capital resources
Alternative cancer treatment modalities (immunotherapy, targeted therapies, CAR-T) potentially reducing radiotherapy utilization and addressable market
Generic radiosensitizers or off-label use of existing drugs potentially limiting pricing power even if approved
Going concern risk - with negative $6M annual operating cash flow and minimal revenue, company requires continuous capital raises; current market cap under $10M suggests limited funding capacity without severe dilution
Warrant overhang - existing warrants may create dilution or downward price pressure if exercised, further compressing per-share value
Negative ROE of -476% and ROA of -302% reflect severe capital destruction; equity holders face near-total loss risk if trials fail or funding exhausted
low - Clinical trial timelines and FDA regulatory processes are largely insulated from GDP fluctuations. However, capital markets access for funding is highly sensitive to risk appetite. During recessions, small-cap biotech funding becomes scarce, increasing bankruptcy risk for pre-revenue companies. The company's ability to raise capital at reasonable valuations depends on broader equity market conditions and biotech sector sentiment.
Rising interest rates negatively impact SHPH through two mechanisms: (1) higher discount rates compress NPV of distant future cash flows, disproportionately affecting pre-revenue biotechs with 5-10 year commercialization timelines, and (2) rates above 4-5% make risk-free Treasuries more attractive than speculative biotech equity, reducing investor appetite for clinical-stage names. The company holds minimal debt (D/E of 0.48), so direct financing cost impact is limited, but equity valuation compression is severe.
Minimal direct credit exposure given limited debt usage. However, credit market conditions indirectly affect biotech venture funding availability. Tight credit conditions reduce institutional risk appetite for speculative growth assets, making equity raises more difficult and dilutive. The company's 1.66 current ratio suggests adequate near-term liquidity, but ongoing cash consumption requires continuous access to capital markets.
momentum/speculative - SHPH attracts high-risk biotech speculators seeking 10-100x returns from clinical trial success, not fundamental value or income investors. The 93.6% one-year decline and negative cash flows eliminate value and dividend investors. Typical holders include retail traders, biotech-focused hedge funds making binary bets, and venture-stage life science funds. Institutional ownership likely minimal given sub-$10M market cap and pre-revenue status.
high - Clinical-stage biotechs exhibit extreme volatility with 50-80% single-day moves common on trial data releases. The -43.8% three-month return and -67.5% six-month return demonstrate persistent downward momentum. Implied volatility likely exceeds 100% annualized. Beta to broader market probably exceeds 2.0, with idiosyncratic risk dominating systematic risk.
